Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1997; 77(05): 1040-1041
DOI: 10.1055/s-0038-1656104
DOI: 10.1055/s-0038-1656104
Letter to the Editor
Characterisation of Fibrinogen Oslo IV by Electrospray Mass Spectrometry
Further Information
Publication History
Received 30 October 1996
Accepted after revision 07 January 1997
Publication Date:
11 July 2018 (online)
-
References
- 1 Stormorken H, Brosstad F, Seim H. A new dysfibrinogenemia: Fibrinogen Oslo IV. Thromb Haemost 1983; 49: 120-122
- 2 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation stie from fibrinogen Canterbury (Aα 20→Val Asp). J Clin Invest 1995; 96: 2854-2858
- 3 Blombäck B, Hessel B, Fields R, Procyk R. Fibrinogen Aarhus: An abnormal fibrinogen with Aα19 Arg→Gly substitution. In: Fibrinogen 3: Biochemical and Biological Function, Gene Regulation and Expression. Mosesson MW, Amrani DL, Siebenlist KR, Di Orio JP. eds. Elsevier Scientific Publishers BV. 1988: 263-266
- 4 Dempfle C-EH, Henschen A. Fibrinogen Mannheim I: Identification of an Aα19→ArgGly substitution in dysfibrinogenaemia associated with bleeding tendency. In: Fibrinogen 4: Current Issues and Clinical Aspects. Matsuda M, Iwanga S, Takada A, Henschen A. eds. Elsevier Scientific Publishers BV. 1990: 159-165
- 5 Yamaguchi FI, Sugo T, Hashimoto Y, Kimura K, Okajima K, Matsuda M. Fibriogen Kumamoto with an A α 19→Gly substitution associated clinically with thrombosis. Fibrinolysis 1996; 10 (Suppl. 04) 23